HRP960339B1 - Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt - Google Patents

Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt

Info

Publication number
HRP960339B1
HRP960339B1 HR960339A HRP960339A HRP960339B1 HR P960339 B1 HRP960339 B1 HR P960339B1 HR 960339 A HR960339 A HR 960339A HR P960339 A HRP960339 A HR P960339A HR P960339 B1 HRP960339 B1 HR P960339B1
Authority
HR
Croatia
Prior art keywords
phenylamino
methylethyl
fluorophenyl
pyrrole
dihydroxy
Prior art date
Application number
HR960339A
Other languages
English (en)
Inventor
Christopher A Briggs
Rex Allen Jennings
Robert A Wade
Kikuko Harasawa
Shigeru Ichikawa
Kazuo Minohara
Shinsuke Nakagawa
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP960339(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP960339A2 publication Critical patent/HRP960339A2/hr
Publication of HRP960339B1 publication Critical patent/HRP960339B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HR960339A 1995-07-17 1996-07-16 Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt HRP960339B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145295P 1995-07-17 1995-07-17

Publications (2)

Publication Number Publication Date
HRP960339A2 HRP960339A2 (en) 1998-04-30
HRP960339B1 true HRP960339B1 (en) 2002-06-30

Family

ID=21696090

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960339A HRP960339B1 (en) 1995-07-17 1996-07-16 Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt

Country Status (38)

Country Link
US (1) US5969156A (no)
EP (2) EP0848705B1 (no)
JP (4) JP3296564B2 (no)
KR (2) KR100431038B1 (no)
CN (1) CN1087288C (no)
AR (2) AR003459A1 (no)
AT (3) ATE208375T1 (no)
AU (1) AU725424B2 (no)
BG (1) BG63630B1 (no)
BR (1) BR9609872A (no)
CA (1) CA2220018C (no)
CO (1) CO4700443A1 (no)
CY (1) CY2358B1 (no)
CZ (3) CZ294108B6 (no)
DE (2) DE69634054T2 (no)
DK (2) DK0848705T3 (no)
EA (1) EA000474B1 (no)
EE (1) EE03606B1 (no)
ES (2) ES2167587T3 (no)
GE (1) GEP20002029B (no)
HK (1) HK1018052A1 (no)
HR (1) HRP960339B1 (no)
HU (1) HU223599B1 (no)
IL (7) IL128862A (no)
MX (1) MX9709099A (no)
NO (1) NO309898B1 (no)
NZ (1) NZ312907A (no)
PE (1) PE1898A1 (no)
PL (1) PL193479B1 (no)
PT (2) PT848705E (no)
RO (1) RO120070B1 (no)
SI (2) SI0848705T1 (no)
SK (1) SK284202B6 (no)
TW (1) TW486467B (no)
UA (1) UA51661C2 (no)
UY (2) UY24285A1 (no)
WO (1) WO1997003959A1 (no)
ZA (1) ZA966044B (no)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
IN191236B (no) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
PT1535613E (pt) * 1999-11-17 2010-10-04 Teva Pharma Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
ES2258030T3 (es) 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
JP2003517038A (ja) * 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6258767B1 (en) * 2000-04-26 2001-07-10 Colgate-Palmolive Co. Spherical compacted unit dose softener
ATE260101T1 (de) 2000-06-09 2004-03-15 Lek Tovarna Farmacevtskih Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR20080036661A (ko) * 2000-12-18 2008-04-28 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
PL365312A1 (en) * 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (en) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carboxylic acid salts of beta-alanine esters or -amides
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
KR100609371B1 (ko) * 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
CA2452678A1 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Combination of eplerenone and an hmg coa reductase inhibitor
PL368647A1 (en) 2001-07-30 2005-04-04 Dr.Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
SK1402004A3 (sk) * 2001-08-16 2005-01-03 Teva Pharmaceutical Industries Ltd. Spôsob prípravy vápenatých solí statinov
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CN100406436C (zh) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
JP4422488B2 (ja) * 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
HUP0201083A2 (hu) * 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
DE60315308T2 (de) * 2002-08-06 2007-12-20 Warner-Lambert Company Llc Verfahren zum herstell von 5-(4-fluorphenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäurephenylamid
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1603554A1 (en) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
BRPI0409333A (pt) * 2003-04-14 2006-04-25 Warner Lambert Co processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1626713A2 (en) * 2003-05-16 2006-02-22 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
CA2539158A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1691803A1 (en) * 2003-12-05 2006-08-23 Warner-Lambert Company LLC N-alkyl pyrroles as hmg-coa reductase inhibitors
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PT1727795E (pt) 2004-03-17 2012-04-11 Ranbaxy Lab Ltd Processo para a produção de atorvastatina cálcica na forma amorfa
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
KR20060133013A (ko) * 2004-04-16 2006-12-22 워너-램버트 캄파니 엘엘씨 신규 이미다졸
US20070225353A1 (en) * 2004-04-16 2007-09-27 Pfizer, Inc. Process for Forming Amorphous Atorvastatin
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
CA2573771C (en) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ES2262459T1 (es) * 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
JP2008510798A (ja) 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
CA2579997A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
TW200630335A (en) 2004-10-18 2006-09-01 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
KR20070067175A (ko) 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
EP1819319A1 (en) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
WO2006059210A2 (en) * 2004-12-03 2006-06-08 Warner-Lambert Company Llc Fused bicyclic pyrrols as hmg-coa reductase inhibitors
EP1671947A1 (en) * 2004-12-20 2006-06-21 Ratiopharm GmbH Process for preparing pyrrole derivatives and intermediates
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
RU2008107336A (ru) * 2005-07-27 2009-09-10 Дов Фармасьютикал, Инк. (Us) Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
EP1928823B1 (en) 2005-08-15 2014-10-08 Arrow International Limited Process for preparing crystalline sodium salt of ATORVASTATIN
CN101268047B (zh) 2005-08-15 2012-11-07 箭锋国际有限公司 结晶和无定形阿托伐他汀钠
WO2007030302A2 (en) * 2005-09-01 2007-03-15 Prescient Medical, Inc. Drugs coated on a device to treat vulnerable plaque
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
US20090018182A1 (en) * 2006-06-28 2009-01-15 Sigalit Levi Crystalline forms of atorvastatin
US7879585B2 (en) 2006-10-02 2011-02-01 Codexis, Inc. Ketoreductase enzymes and uses thereof
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
PT103661B (pt) * 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
AP2009005026A0 (en) * 2007-04-09 2009-12-31 Scidose Llc Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
ES2449483T3 (es) 2007-07-26 2014-03-19 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
CA2700227A1 (en) 2007-09-21 2009-04-02 Epiphany Biosciences, Inc. Valomaciclovir polymorphs
KR100813666B1 (ko) 2007-10-23 2008-03-14 (주)에이에스텍 콜레스테롤 합성 저해제로서 아토르바스타틴의 프로드럭
DE102007052071A1 (de) * 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2285352A2 (en) * 2008-05-13 2011-02-23 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2805292A1 (en) * 2010-09-30 2012-04-05 Wisconsin Alumni Research Foundation (20r,25s)-2-methylene-19,26-dinor-1.alpha.,25-dihydroxyvitamin d3 in crystalline form
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
US20120165386A1 (en) * 2010-12-27 2012-06-28 Ranbaxy Laboratories Limited Stable oral pharmaceutial composition of atorvastatin
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
EP2788384B1 (en) 2011-12-08 2017-08-09 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
WO2013164257A1 (en) 2012-04-30 2013-11-07 F. Hoffmann-La Roche Ag New formulation
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CA2958898A1 (en) 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CA3063439A1 (en) 2017-05-30 2018-12-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of neuroinflammatory disease
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
CN108558726A (zh) * 2018-03-14 2018-09-21 湖北广济药业股份有限公司 一种高纯度阿托伐他汀钙的制备方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
KR20210001641U (ko) 2020-01-08 2021-07-16 주식회사 다마가산업 최소구성의 초저가 콘크리트 타설 레벨표시구
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456753A (en) 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
JP2003517038A (ja) 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
ES2258030T3 (es) 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
KR100609371B1 (ko) 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태

Also Published As

Publication number Publication date
SI1148049T1 (en) 2005-02-28
AR003458A1 (es) 1998-08-05
ATE284868T1 (de) 2005-01-15
AT8453U1 (de) 2006-08-15
JP2014051533A (ja) 2014-03-20
ATE208375T1 (de) 2001-11-15
JP2003073353A (ja) 2003-03-12
EA199800130A1 (ru) 1998-08-27
CO4700443A1 (es) 1998-12-29
AU725424B2 (en) 2000-10-12
HU223599B1 (hu) 2004-10-28
CZ294108B6 (cs) 2004-10-13
SI0848705T1 (en) 2002-04-30
ZA966044B (en) 1997-02-03
IL122118A (en) 1999-07-14
IL128862A0 (en) 2000-01-31
IL177376A0 (en) 2006-12-10
CN1087288C (zh) 2002-07-10
IL128865A (en) 2006-04-10
MX9709099A (es) 1998-02-28
TW486467B (en) 2002-05-11
WO1997003959A1 (en) 1997-02-06
DE69634054D1 (de) 2005-01-20
PT848705E (pt) 2002-02-28
PL324496A1 (en) 1998-05-25
KR100389518B1 (ko) 2003-11-15
IL128864A (en) 2007-10-31
NZ312907A (en) 2000-12-22
BG63630B1 (bg) 2002-07-31
EP0848705B1 (en) 2001-11-07
CN1190955A (zh) 1998-08-19
EE03606B1 (et) 2002-02-15
PE1898A1 (es) 1998-03-04
CY2358B1 (en) 2004-06-04
KR20030097628A (ko) 2003-12-31
PL193479B1 (pl) 2007-02-28
CZ12198A3 (cs) 1998-10-14
NO980207D0 (no) 1998-01-16
BG102187A (en) 1998-10-30
PT1148049E (pt) 2005-02-28
JP4790194B2 (ja) 2011-10-12
DE69634054T2 (de) 2005-12-08
IL128864A0 (en) 2000-01-31
JPH11509230A (ja) 1999-08-17
DE69616808D1 (en) 2001-12-13
IL177377A0 (en) 2006-12-10
AR003459A1 (es) 1998-08-05
CZ294695B6 (cs) 2005-02-16
RO120070B1 (ro) 2005-08-30
NO309898B1 (no) 2001-04-17
HRP960339A2 (en) 1998-04-30
EP0848705A1 (en) 1998-06-24
EP1148049A1 (en) 2001-10-24
GEP20002029B (en) 2000-04-10
CZ294740B6 (cs) 2005-03-16
IL128865A0 (en) 2000-01-31
ES2233526T3 (es) 2005-06-16
AU6484296A (en) 1997-02-18
DK1148049T3 (da) 2005-03-29
US5969156A (en) 1999-10-19
HUP9900678A2 (hu) 1999-07-28
UA51661C2 (uk) 2002-12-16
CA2220018C (en) 2001-04-17
ES2167587T3 (es) 2002-05-16
UY24285A1 (es) 1997-01-17
IL122118A0 (en) 1998-04-05
UY24985A1 (es) 2001-03-16
HUP9900678A3 (en) 2000-04-28
HK1018052A1 (en) 1999-12-10
IL128862A (en) 2007-12-03
CA2220018A1 (en) 1997-02-06
EE9800015A (et) 1998-08-17
DK0848705T3 (da) 2002-02-04
SK6298A3 (en) 1998-10-07
BR9609872A (pt) 1999-03-23
KR19990029043A (ko) 1999-04-15
EP1148049B1 (en) 2004-12-15
IL203847A0 (en) 2011-08-01
EA000474B1 (ru) 1999-08-26
DE69616808T2 (de) 2002-05-29
NO980207L (no) 1998-01-16
JP2011195592A (ja) 2011-10-06
SK284202B6 (sk) 2004-10-05
KR100431038B1 (ko) 2004-05-12
JP3296564B2 (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
HRP960339B1 (en) Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt
IL122161A0 (en) Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3- phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid calcium salt (2:1)
PL367943A1 (en) Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
PL324532A1 (en) Crystalline form iii of semi-calcinius salt of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrolo-1-heptanic acid
PL370061A1 (en) Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
NO975499D0 (no) Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-<beta>-<delta>-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt
SI0848704T1 (en) Form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150709

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20160716